Compare BAND & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | IMMX |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.9M | 629.3M |
| IPO Year | 2017 | 2021 |
| Metric | BAND | IMMX |
|---|---|---|
| Price | $63.79 | $8.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $24.50 | $19.20 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $204,113,000.00 | N/A |
| Revenue This Year | $15.16 | N/A |
| Revenue Next Year | $6.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $12.50 | $1.94 |
| 52 Week High | $75.98 | $11.61 |
| Indicator | BAND | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 57.34 | 39.74 |
| Support Level | $14.27 | $3.98 |
| Resistance Level | N/A | $10.61 |
| Average True Range (ATR) | 5.94 | 0.66 |
| MACD | -1.50 | -0.07 |
| Stochastic Oscillator | 35.40 | 21.23 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of its revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.